Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

OBJECTIVES: In the ‘Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism’ (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients wi...

Full description

Saved in:
Bibliographic Details
Published in:BMJ Open
Main Authors: de Jong, Lisa A, van der Velden, Annette W G, van Hulst, Marinus, Postma, Maarten J
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2020
Subjects:
Health Economics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7678368/
https://ncbi.nlm.nih.gov/pubmed/33444193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-039057
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items